ReviewNature reviews. Neurology2026
Epidemiology and characteristics of multiple sclerosis in Latin America.
Review in Nature reviews. Neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
According to the MS International Federation, the global prevalence of multiple sclerosis (MS) is increasing, although regional variations have been reported, which could provide valuable insights into MS pathophysiology. As we highlight in this Review, the prevalence of MS in Latin America is comparatively low, possibly owing at least in part to the unique genetic and environmental characteristics of this region. Latin America has experienced centuries of admixture between Native American Indian populations and people from other parts of the world, including Europe and - to a lesser extent - Africa. Moreover, certain environmental factors in the Southern Hemisphere might contribute to this reduced MS prevalence. The McDonald criteria are considered to be a useful tool to diagnose MS in Latin America, although it is important to exclude regional diseases that can mimic MS. MS research is burgeoning in the region, and increasing numbers of Latin American patients are participating in randomized clinical trials. In addition, real-world data from national and regional MS registries are helping us to understand the distinct features of the disease in Latin America.
Indexed as
Identifiers
41249588What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.